[Sha Tin, 10/22/25] In an era where advanced cell and gene therapies are reshaping modern medicine, Cryogenic Storage has emerged as a cornerstone technology ensuring the safety, viability, and quality of biological materials. From stem cells and tissue samples to gene-modified therapies, maintaining ultra-low temperature environments is critical to preserving their functionality and long-term stability.
Cryogenic storage systems play a vital role in protecting sensitive biological products used in cell therapy, biobanking, and clinical research. By keeping materials at temperatures below -150°C, these systems effectively halt all biological activity, preventing degradation and ensuring the integrity of precious samples over extended periods.
Modern advancements have made cryogenic storage more efficient, scalable, and secure. Automated cryogenic systems equipped with digital monitoring and alarm features are now minimizing risks of temperature fluctuations and human error. This not only enhances sample traceability but also ensures full compliance with Good Manufacturing Practices (GMP) and regulatory standards.
As the biopharma industry expands rapidly, the demand for reliable and compliant cryogenic infrastructure continues to rise. Pharmaceutical companies, research institutions, and CDMOs are increasingly investing in robust cold-chain storage systems to support the growing need for long-term preservation of high-value therapeutics.
Moreover, innovations in liquid nitrogen-based storage, energy-efficient cooling technologies, and smart tracking solutions are revolutionizing the way biological materials are handled and maintained. These improvements are not only driving operational excellence but also reducing energy consumption and environmental impact.
Cryogenic storage is more than a preservation method—it’s an enabler of progress in regenerative medicine, gene therapy, and clinical research. By ensuring the highest standards of sample integrity, it supports every stage of biopharmaceutical development, from preclinical testing to large-scale commercial production.
As one of the emerging leaders in advanced therapy manufacturing, Xellera Therapeutics emphasizes the importance of secure and compliant cryogenic storage to ensure product quality, patient safety, and regulatory reliability. The company’s integrated infrastructure is designed to support global partners in storing, developing, and delivering life-changing therapies with precision and confidence.

About Xellera Therapeutics
Xellera Therapeutics is a leading CDMO specializing in Cell and Gene Therapy (CGT) and Advanced Therapy Products (ATP). Through its GMP-compliant manufacturing facilities and state-of-the-art cryogenic storage systems, Xellera supports partners worldwide in translating scientific breakthroughs into safe, effective, and accessible treatments.

Contact: 604-760-2937
Your Name: Xellera Therapeutics
Your Title: Advancing Biopharma Safety and Longevity with Next-Generation Cryogenic Storage Solutions
Email: [email protected]
Website: https://www.xelleratherapeutics.com/facilities/